In vivo efficacy of XR9051, a potent modulator of P-glycoprotein mediated multidrug resistance

British Journal of Cancer

Volumn 79, Issue 11-12, 1999, Pages 1672-1678

  Mistry, P ^a   Plumb, J ^b   Eccles, S ^c   Watson, S ^d   Dale, I ^a   Ryder, H ^a   Box, G ^c   Charlton, P ^a   Templeton, D ^a   Bevan, P B ^a  

^a Cantab Pharmaceuticals Ltd   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Multidrug resistance; P glycoprotein; Resistance modulators; XR9051

Indexed keywords

BENZAMIDE DERIVATIVE; CYTOTOXIC AGENT; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; UNCLASSIFIED DRUG; VINCRISTINE; XR 9051;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESISTANCE; DRUG TOLERABILITY; DRUG TUMOR LEVEL; FEMALE; GENE OVEREXPRESSION; IN VIVO STUDY; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; LUNG SMALL CELL CANCER; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; ORAL DRUG ADMINISTRATION; OVARY CARCINOMA; PRIORITY JOURNAL; TUMOR XENOGRAFT;

EID: 0032995991     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690267     Document Type: Article

References (21)

1. Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P and Loor F (1991) In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumour cells with SDZ PSC 833. Cancer Res 51: 4226-4233
2. Childs S and Ling V (1994) The MDR superfamily of genes and its biological implications. In Important Advances in Oncology, De Vita VT, Hellman S and Rosenberg SA (eds), pp. 21-36. Lippincott Co: Philadelphia
3. Colombo T, Paz OG and D'Incalci M (1996) Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia. Br J Cancer 73: 866-871
4. Cros S, Guilbaud N, Berlion M, Dunn T, Regnier G, Dhainaut A, Atassi G and Bizzari JP (1992) In vivo evidence of complete circumvention of vincristine resistance by a new triazinoaminopiperidine derivative S9788 in P388/VCR leukaemia model. Cancer Chemother Pharmacol 30: 491-494
5. Dale IL, Tuffley W, Callaghan R, Holmes JA, Martin K, Luscombe M, Mistry P, Ryder H, Stewart AJ, Charlton P, Twentyman PR and Bevan P (1998) Reversal of P-glycoprotein (P-gp)-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative. Br J Cancer 78: 885-892
6. Dalton WS (1994) Is p-glycoprotein a potential target for reversing clinical drug resistance? Curr Opin Oncol 6: 595-600
7. Dantzig AH, Shepard RL, Cao J, Law KL, Ehlhardt WJ, Baughman TM, Bumol TF and Starling JJ (1996) Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 56: 4171-4179
8. Ferry DR, Traunecker H and Kerr DJ (1996) Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer 32A: 1070-1081
9. Germann UA (1996) P-glycoprotein: a mediator of multidrug resistance in tumour cells. Eur J Cancer 32A: 927-944
10. Gottesman MM and Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann Rev Biochem 62: 385-427
11. Hyafil F, Vergely C, Du Vignaud P and Grand-Perret T (1993) In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 53: 4595-4602
12. Johnson RK, Chitnis MP Embrey WM and Gregory EB (1978) In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukaemia. Cancer Treat Rep 62: 1535-1547
13. Lum BL, Fisher GA, Brophy NA, Yahanda AM, Adler KM, Kaubisch S, Halsey J and Sikic BI (1993) Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. Cancer 72: 3502-3514
14. Plumb JA, Wishart GC, Setanoians A, Morrison JG, Hamilton TN, Bicknell SR and Kaye SB (1994) Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro, toxicity in vivo and growth delay in a solid human tumour xenograft. Biochem Pharmacol 47: 257-266
15. Sato W, Fukazawa N, Nakanishi O, Baba M, Suzuki T, Yano O, Naito M and Tsuruo T (1995) Reversal of multidrug resistance by a novel quinoline derivative, MS-209. Cancer Chemother Pharmacol 15: 271-277
16. Shinoda H, Inaba M and Tsuruo T (1989) In vivo circumvention of vincristine resistance in mice with P388 leukaemia using a novel compound AHC-52. Cancer Res 49: 1722-1726
17. Spoelstra EC, Dekker H, Schuurhuis GJ, Broxterman HJ and Lankelma J (1991) P-glycoprotein efflux pump involved in the mechanism of intrinsic drug resistance in various colon cancer cell lines. Evidence for a saturation of active daunorubicin transport. Biochem Pharmacol 41: 349-359
18. Tsuruo T, Iida H, Tsukagoshi S and Sakurai Y (1981) Overcoming of vincristine resistance in P388 leukaemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967-1972
19. Twentyman PR, Fox NE, Wright KA and Bleehen NM (1986) Derivation and preliminary characterisation of adriamycin resistant lines of human lung cancer cells. Br J Cancer 53: 529-537
20. Wacher VJ, Wu CY and Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13: 129-134
21. Yang J-M, Goldenberg S, Gottesman MM and Hail WN (1994) Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. Cancer Res 54: 730-737